Acne Treatments - Drugs Can Not Help Asthma Patients With Acne

Acne Treatments 

The medication against asthma Zyflo fails to help patients with severe acne after a mid-stage trial conducted by the company critical Therapeutics Inc. The drug, also known as zileuton, was neither better control the number of inflammatory lesions than placebo statistics of the company.

During the 12-week trials, patients treated with Zyflo had an average reduction of 11.5 inflammatory lesions. This compares with a reduction of 9.1 lesions in a group of other patients taking placebos - far from reaching statistical significance.

Patients treated with placebo showed a reduction of 16.4 lesions in the placebo group, but patients with Zyflo showed an average reduction of the total number of lesions in 25.3.

The company said it showed a trend in medicine can be useful for some patients, even if the medicine is not a main objective of the process.

Linda Lennox, a company spokesman, said the company will probably do more tests to test the drug for the treatment of acne, using information from the last small "proof of concept" test.

The company is headquartered in Lexington, Mass., said it will continue to analyze the data and the scientists who work to interpret the results.

Zyflo blocks an inflammation that causes the enzyme 5 lipoxygenase (5-LO). It was approved by U.S. authorities in 1996 to treat patients with asthma for 12 years and over. At that time, the drug from Abbott Laboratories Inc., which sold for several years before licensing Therapeutics criticism in late 2011.